Adalimumab-Associated Risks and Monitoring Requirements

Introduction to Adalimumab-Associated Risks

Gastrointestinal symptoms, including nausea and upset, are associated with adalimumab treatment 1
Cytopenias, including pancytopenia, can occur, though relatively uncommon, with adalimumab treatment 1
Thromboembolic events have a hazard ratio of 7.6 in patients developing anti-adalimumab antibodies 1
The American Society of Clinical Oncology recommends hematology consultation for serious hematologic effects and potential treatment discontinuation 1

TB screening is mandatory before initiating therapy with tuberculin skin testing and chest radiograph 2
Serious infection rate of 2.03 per 100 patient-years in long-term studies 2
Risk includes Legionella pneumophila pneumonia, Pneumocystis jirovecii pneumonia, and atypical mycobacteria 2
Deep fungal infections, particularly in endemic areas, are a risk associated with adalimumab treatment 2
Hepatitis serology is required before treatment initiation 2

Lupus-like syndrome has been reported in 15 patients with adalimumab in systematic analysis 2
Vasculitis has been reported in five cases with adalimumab in detailed analysis 2
Drug-specific risk of vasculitis is documented in rheumatoid arthritis patients 3, 4

Pulmonary fibrosis can occur as a new event or exacerbation of underlying fibrosis 2
Interstitial pneumonias have been reported in at least 18 patients receiving anti-TNF agents 2
Sarcoidosis cases have been reported, with an unclear mechanism 2

Pre-treatment screening should include tuberculin skin testing and chest radiograph 2
Pre-treatment screening should include hepatitis B serology 2
Patient education priorities include reporting fever, infection signs, and avoiding live vaccines during therapy 2

Adalimumab is classified as FDA Category B for all trimesters 2
Increased first trimester miscarriage rate has been reported 2
Safety in breastfeeding is unknown, with antibodies secreted in milk, and caution is recommended 5